<DOC>
	<DOCNO>NCT01823536</DOCNO>
	<brief_summary>In extension study , V59P20E1 , sponsor planning assess 5-year antibody persistence subject receive one two dos MenACWY conjugate vaccine 2 10 year age , evaluate response booster dose administer 5 year primary vaccination parent study V59P20 ( NCT00616421 ) .</brief_summary>
	<brief_title>Persistence Immunogenicity MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination , Immune Response Booster Dose</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>In order participate study , subject must meet ALL inclusion criterion describe . 1 . Subject ( ) parent ( ) legal guardian ( ) has/have give write consent nature study explain accord local regulatory requirement . 2 . If subject age , accord local regulation , inform assent require , subject provide assent participate study . 3 . Subject good health determine outcome medical history , physical examination , clinical judgment investigator . 4 . A negative urine pregnancy test require female subject childbearing potential enrol . Of childbearing potential defined status post onset menarche meeting follow condition : menopausal least 2 year , status bilateral tubal ligation least 1 year , status bilateral oophorectomy , status hysterectomy . 5 . For subject participate study V59P20 ( Groups MenACWYCRM_ 2 ( ≥7≤10 Years ) , MenACWYCRM_1 ( ≥7≤10 Years ) MenACWYCRM_ 1 ( ≥11≤15 Years ) ) : subject enrol Groups MenACWYCRM_2 ( ≥7≤10 Years ) , MenACWYCRM_1 ( ≥7≤10 Years ) MenACWYCRM_1 ( ≥11≤15 Years ) study V59P20 , complete study include per protocol immunogenicity analysis ; date first vaccination study V59P20 occur 54 66 month prior collection blood sample Visit 1 . 6 . For vaccinenaive subject ( Groups Vaccine Naive ( ≥7≤10Years ) Vaccine Naive ( ≥11≤15 Years ) ) : Individual male female 7 10 year age ( group Vaccine Naive ( ≥7≤10Years ) ) 11 15 year age ( Group Vaccine Naive ( ≥11≤15 Years ) ) . In order participate study , subject must meet NONE exclusion criterion describe . 1 . If subject female childbearing potential , sexually active , use acceptable contraceptive method least 2 month prior study entry duration trial . 2 . Subject pregnant breastfeeding female . 3 . Subjects ' parent legal guardian subject able comprehend follow require study procedure whole period study . 4 . History document suspected invasive meningococcal disease . 5 . Previous household contact and/or intimate exposure individual laboratory proven N. meningitidis infection within 60 day prior enrollment duration study . 6 . Have receive meningococcal vaccine since participation V59P20 , vaccinenaive subject , receive meningococcal vaccine since birth . 7 . Suspected known hypersensitivity reaction previous dose Menveo , component vaccine , include CRM197 diphtheria toxoid . 8 . Any contraindication precaution vaccination Novartis Menveo™ vaccine highlight package insert . 9 . Serious , chronic , acute illness disease ( i.e. , cardiac , renal , neurologic , rheumatologic , metabolic , gastrointestinal , psychiatric , organ system ) . 10 . Any confirmed suspected condition impaired/altered function immune system ( immunodeficient autoimmune condition ) . 11 . Administration cancer chemotherapy , immunemodified immunosuppressive agent systemic corticosteroid least seven day dose past 12 week plan use throughout study period ( nasal inhale steroid permit , steroid apply skin ) . 12 . Administration blood , blood product and/or plasma derivative immunoglobulin preparation past 12 week plan use throughout study period . 13 . Administration vaccine within 28 day prior study enrollment plan administration study period . 14 . Subjects participate clinical trial another investigational product 28 day prior first study visit intent participate another clinical study time study period . 15 . Subjects experience significant acute infection require systemic antibiotic treatment within 5 day prior enrolment experience body temperature ≥38°C ( ≥100.4°F ) within 3 day intend study vaccination . 16 . Any condition , opinion investigator , would pose health risk participant .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Meningitis</keyword>
</DOC>